Katherine Bach Kalin
CIK: 0001832671
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
SELLAS Life Sciences Group, Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jan 7, 2026SLS
SELLAS Life Sciences Group, Inc.
Award(A)Direct50K shares- - Nov 19, 2025SLS
SELLAS Life Sciences Group, Inc.
Purchase(P)Direct63.4K shares at avg. $1.59$101K - May 22, 2025SLS
SELLAS Life Sciences Group, Inc.
Purchase(P)Direct20K shares at avg. $1.80$36K - Jan 10, 2025SLS
SELLAS Life Sciences Group, Inc.
Award(A)Direct12.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 7, 2026 | SLS SELLAS Life Sciences Group, Inc. | Award(A) | 50,000 | - | $0 | Direct |
| Nov 19, 2025 | SLS SELLAS Life Sciences Group, Inc. | Purchase(P) | 63,400 | $1.59 | $100,806 | Direct |
| May 22, 2025 | SLS SELLAS Life Sciences Group, Inc. | Purchase(P) | 20,000 | $1.80 | $36,000 | Direct |
| Jan 10, 2025 | SLS SELLAS Life Sciences Group, Inc. | Award(A) | 12,500 | - | $0 | Direct |
1-4 of 4 transactions
About Kalin Katherine Bach
Kalin Katherine Bach (SEC CIK 0001832671) files insider reports with the SEC as Director of SELLAS Life Sciences Group, Inc. (SLS).
Signal8 holds 4 ownership filings by Kalin Katherine Bach, all Form 4s, filed between Jan 14, 2025 and Jan 9, 2026. Those filings report 4 transactions, from Jan 10, 2025 to Jan 7, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Kalin Katherine Bach's filings is in NEW YORK, NY.
Recent filings by Kalin Katherine Bach
Other insiders filing for SELLAS Life Sciences Group, Inc. (SLS)
- Stergiou Angelos M., President and CEO
- Varian John, Director
- VAN NOSTRAND ROBERT L, Director
- SCHEINBERG DAVID A, Director
- CICIC DRAGAN, SVP, Chief Development Officer
- Burns John Thomas, CFO